SLC5A2 and heart failure: In the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure (DAPA-HF) trial, which investigated whether the SGLT2 inhibitor dapagliflozin improves cardiovascular outcomes in patients with chronic heart failure with reduced left ventricular ejection fraction, 43.7% of patients had iron deficiency according to the above definition [39].